Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.

Saved in:
Bibliographic Details
Title: Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.
Authors: Garcia-Manero G; MD Anderson Cancer Center, Houston, TX, USA. ggarciam@mdanderson.org., Santini V; MDS Unit, DMSC, University of Florence, AOUC, Florence, Italy., Zeidan AM; Yale School of Medicine, New Haven, CT, USA., Komrokji RS; Moffitt Cancer Center, Tampa, FL, USA., Pozharskaya V; Bristol Myers Squibb, Princeton, NJ, USA., Rose S; Bristol Myers Squibb, Princeton, NJ, USA., Keeperman K; Bristol Myers Squibb, Princeton, NJ, USA., Lai Y; Bristol Myers Squibb, Princeton, NJ, USA., Kalsekar S; Bristol Myers Squibb, Hyderabad, India., Aggarwal B; Bristol Myers Squibb, Princeton, NJ, USA., Miteva D; Bristol Myers Squibb, Boudry, Switzerland., Valcárcel D; Vall d'Hebron, Institute of Oncology (VHIO), Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Fenaux P; AP-HP St Louis, Paris, France., Shortt J; Monash Health and Monash University, Clayton, VIC, Australia., Della Porta MG; Humanitas University, Milan, Italy., Platzbecker U; University Hospital Dresden, Dresden, Germany.
Source: Advances in therapy [Adv Ther] 2025 Jul; Vol. 42 (7), pp. 3576-3589. Date of Electronic Publication: 2025 May 16.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1865-8652
DOI:10.1007/s12325-025-03208-5